References in periodicals archive ?
Jevtana was found to significantly increase the overall survival rate in men diagnosed with mHRPC whose disease has progressed during or after treatment with docetaxel.
Results from this trial demonstrated a statistically significant 30% reduction in risk of death from mHRPC among patients taking Jevtana in combination with prednisone compared with an active chemotherapy regimen consisting of a standard dose of mitoxantrone and prednisone.
Several prognostic factors in hormone-refractory prostate cancer (HRPC) have been reported, including initial PSA, tumour Gleason grade and stage, as well as baseline hemoglobin, performance status and PSA doubling time (PSADT).[sup.7,8] PSA response (defined as a 50% decline in baseline PSA) has also been proposed as a predictor of survival following chemotherapy for mHRPC.[sup.9] However, the magnitude of this benefit has been variable between studies and there is a need for better predictors of outcome from chemotherapy in mHRPC.[sup.10]-[sup.12]
After receiving docetaxel chemotherapy for mHRPC, patients differ not only in their percent PSA decline, but also in the rate at which they achieve this decline.
Inclusion criteria for the study were: confirmation of mHRPC by 3 sequential rises in PSA with a castrate level of serum testosterone (<50 ng/dL) and metastatic disease on imaging (x-ray, computed tomography or bone scan).